Vicarious Surgical’s Beta 2 surgical robotic system. | Credit score: Vicarous Surgical
Vicarious Surgical (NYSE:RBOT) introduced that the NYSE has commenced the method of delisting its inventory.
The Waltham, Massachusetts–based mostly surgical robotic developer obtained a discover from the inventory change yesterday, March 3, 2026. On account of the NYSE motion, the corporate’s inventory was suspended after market shut.
Shares of RBOT are presently buying and selling at $1.92 apiece forward of the opening of the NYSE market immediately.
Vicarious stated that the NYSE decided that its inventory fell beneath the continued itemizing commonplace. It requires corporations to take care of a median world market capitalization over a consecutive 30-day buying and selling interval of not less than $15 million.
The corporate should make an enchantment inside 10 enterprise days from receipt of the discover. It stated it presently has a possible enchantment beneath analysis. In the meantime, the corporate obtained approval to have its inventory quoted on the OTCID market tier operated by the OTC Markets Group. It expects widespread inventory to start citation on that market on the open of enterprise immediately, March 4, 2026. The corporate intends to proceed buying and selling beneath the “RBOT” ticker.
This isn’t the primary time the corporate has confronted delisting, having fallen beneath NYSE requirements in 2023. It then performed a reverse inventory break up halfway by 2024.
The most recent on Vicarious Surgical’s efforts
Potential delisting comes at an fascinating time for Vicarious, which has been advancing a surgical robotic platform for a while, however has hit numerous snags alongside the way in which.
Vicarious designed its robotic to extend the effectivity of surgical procedures. The corporate beforehand set its sights on first-in-human trials halfway by 2025, however delayed the robotic’s timeline again in November 2023. Then, in March 2024, the corporate outlined plans to have its “V1.0” system prepared for an FDA submission by early to mid-fiscal 2026.
In late 2024, the corporate stated it deliberate for a year-end cadaver lab for V1.0, adopted by efforts towards verification, validation, and optimization of the system forward of formal medical testing. In Could 2025, Vicarious introduced a brand new hospital collaboration, shifting nearer to bringing its surgical robotic know-how to sufferers. However, in August, the corporate stated it could maintain off on medical trial initiation to additional develop its robotic. At the moment, the corporate earmarked the tip of 2026 for its design freeze.
Firstly of this 12 months, the corporate efficiently accomplished an in-vivo porcine lab for the robotic. It stated the lab reinforces its progress towards a system design freeze earmarked for the tip of 2026.
